dc.contributor.author | Dréno, B | |
dc.contributor.author | Ascierto, PA | |
dc.contributor.author | Atkinson, V | |
dc.contributor.author | Liszkay, G | |
dc.contributor.author | Maio, M | |
dc.contributor.author | Mandalà, M | |
dc.contributor.author | Demidov, L | |
dc.contributor.author | Stroyakovskiy, D | |
dc.contributor.author | Thomas, L | |
dc.contributor.author | de la Cruz-Merino, L | |
dc.contributor.author | Dutriaux, C | |
dc.contributor.author | Garbe, C | |
dc.contributor.author | Bartley, K | |
dc.contributor.author | Karagiannis, T | |
dc.contributor.author | Chang, I | |
dc.contributor.author | Rooney, I | |
dc.contributor.author | Koralek, DO | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | McArthur, GA | |
dc.contributor.author | Ribas, A | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-08-22T13:18:21Z | |
dc.date.available | 2022-08-22T13:18:21Z | |
dc.date.issued | 2018-03-20 | |
dc.identifier | bjc2017488 | |
dc.identifier.citation | British Journal of Cancer, 2018, 118 (6), pp. 777 - 784 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5296 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.doi | 10.1038/bjc.2017.488 | |
dc.description.abstract | BACKGROUND: In the coBRIM study, cobimetinib plus vemurafenib (C+V) significantly improved survival outcomes vs placebo and vemurafenib (P+V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis of health-related quality of life (HRQOL) from coBRIM is reported. METHODS: Patients completing the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) at baseline and ⩾1 time point thereafter constituted the analysis population. Change from baseline ⩾10 points was considered clinically meaningful. RESULTS: Mean baseline scores for all QLQ-C30 domains were similar between arms. Most on-treatment scores for QLQ-C30 domains were also comparable between arms. A transient deterioration in role function in cycle 1 day 15 (C1D15; -14.7 points) in the P+V arm and improvement in insomnia in the C+V arm at C2D15 (-12.4 points) was observed. Among patients who experienced a ⩾10-point change from baseline (responders), between-group differences were greatest for insomnia (16%), social functioning (10%), fatigue (9%) and pain (7%), all favouring C+V. Diarrhoea, photosensitivity reaction, pyrexia, and rash did not meaningfully affect global health status (GHS). Serous retinopathy was associated with a transient decrease in GHS at C1D15 assessment. CONCLUSIONS: In patients with advanced/metastatic BRAFV600-mutated melanoma, treatment with C+V maintained HRQOL compared with P+V, with superior efficacy. | |
dc.format | Print-Electronic | |
dc.format.extent | 777 - 784 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.relation.ispartof | British Journal of Cancer | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Azetidines | |
dc.subject | Double-Blind Method | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Longitudinal Studies | |
dc.subject | Male | |
dc.subject | Melanoma | |
dc.subject | Mutation | |
dc.subject | Piperidines | |
dc.subject | Placebos | |
dc.subject | Proto-Oncogene Proteins B-raf | |
dc.subject | Quality of Life | |
dc.subject | Vemurafenib | |
dc.title | Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-12-15 | |
dc.date.updated | 2022-08-22T13:17:15Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1038/bjc.2017.488 | |
rioxxterms.licenseref.startdate | 2018-03-20 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/29438370 | |
pubs.issue | 6 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.publication-status | Published | |
pubs.volume | 118 | |
dc.contributor.icrauthor | Larkin, James | |
icr.provenance | Deposited by Mr Arek Surman on 2022-08-22. Deposit type is initial. No. of files: 1. Files: Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic.pdf | |